BACKGROUND: The clinical CardShock risk score, including baseline lactate levels, was recently shown to facilitate risk stratification in patients with cardiogenic shock (CS). As based on baseline parameters, however, it may not reflect the change in mortality risk in response to initial therapies. Adrenomedullin is a prognostic biomarker in several cardiovascular diseases and was recently shown to associate with hemodynamic instability in patients with septic shock. The aim of our study was to evaluate the prognostic value and association with hemodynamic parameters of bioactive adrenomedullin (bio-ADM) in patients with CS. METHODS: CardShock was a prospective, observational, European multinational cohort study of CS. In this sub-analysis, serial plasma bio-ADM and arterial blood lactate measurements were collected from 178 patients during the first 10 days after detection of CS. RESULTS: Both bio-ADM and lactate were higher in 90-day non-survivors compared to survivors at all time points (P < 0.05 for all). Lactate showed good prognostic value during the initial 24 h (AUC 0.78 at admission and 0.76 at 24 h). Subsequently, lactate returned normal (≤2 mmol/L) in most patients regardless of later outcome with lower prognostic value. By contrast, bio-ADM showed increasing prognostic value from 48 h and beyond (AUC 0.71 at 48 h and 0.80 at 5-10 days). Serial measurements of either bio-ADM or lactate were independent of and provided added value to CardShock risk score (P < 0.001 for both). Ninety-day mortality was more than double higher in patients with high levels of bio-ADM (>55.7 pg/mL) at 48 h compared to those with low bio-ADM levels (49.1 vs. 22.6%, P = 0.001). High levels of bio-ADM were associated with impaired cardiac index, mean arterial pressure, central venous pressure, and systolic pulmonary artery pressure during the study period. Furthermore, high levels of bio-ADM at 48 to 96 h were related to persistently impaired cardiac and end-organ function. CONCLUSIONS: Bio-ADM is a valuable prognosticator and marker of impaired hemodynamics in CS patients. High levels of bio-ADM may show shock refractoriness and developing end-organ dysfunction and thus help to guide therapeutic approach in patients with CS. Study identifier of CardShock study NCT01374867 at clinicaltrials.gov.

Department of Anesthesia and Critical Care University Hospital Saint Louis Lariboisière APHP Paris France

Department of Cardiology CINTESIS Porto Medical School São João Hospital Center University of Porto Porto Portugal

Department of Cardiology Rigshospitalet University of Copenhagen Copenhagen Denmark

Department of Cardiology University Heart Center 8091 Zürich Switzerland

Department of Cardiology University Hospital Zürich 8091 Zürich Switzerland

Department of Clinical Chemistry University of Eastern Finland Kuopio Finland

Department of Emergency Care Helsinki University and Helsinki University Hospital Helsinki Finland

Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic

Division of Cardiology Department of Medical and Surgical Specialties Radiological Sciences and Public Health University and Civil Hospital of Brescia Brescia Italy

Eastern Finland Laboratory Centre Kuopio Finland

Heart and Lung Center Helsinki University and Helsinki University Hospital Helsinki Finland

Heart Center Päijät Häme Central Hospital Lahti Finland

Heart Failure Clinic and Secondary Cardiology Department Attikon University Hospital Athens Greece

INSERM UMR S942 Paris France

Intensive Cardiac Care Unit Cardiology Department Hospital de la Santa Creu i Sant Pau Biomedical Research Institute IIB SantPau Universidad Autónoma de Barcelona Barcelona Spain

Intensive Cardiac Therapy Clinic Institute of Cardiology Warsaw Poland

International Clinical Research Centre Brno Czech Republic

Medical Clinic 2 University Hospital Schleswig Holstein University Heart Center Lübeck Lübeck Germany

Sphingotec GmbH Hennigsdorf Germany

University Paris Diderot Sorbonne Paris Cité Paris France

Zobrazit více v PubMed

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–1296. doi: 10.1056/NEJMoa1208410. PubMed DOI

Harjola VP, Lassus J, Sionis A, Kober L, Tarvasmaki T, Spinar J, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501–509. doi: 10.1002/ejhf.260. PubMed DOI

Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686–697. doi: 10.1161/CIRCULATIONAHA.106.613596. PubMed DOI

Bakker J, Gris P, Coffernils M, Kahn RJ, Vincent JL. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg. 1996;171(2):221–226. doi: 10.1016/S0002-9610(97)89552-9. PubMed DOI

Attana P, Lazzeri C, Chiostri M, Picariello C, Gensini GF, Valente S. Lactate clearance in cardiogenic shock following ST elevation myocardial infarction: a pilot study. Acute Card Care. 2012;14(1):20–26. doi: 10.3109/17482941.2011.655293. PubMed DOI

Zhang Z, Xu X. Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis*. Crit Care Med. 2014;42(9):2118–2125. doi: 10.1097/CCM.0000000000000405. PubMed DOI

Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Yano K. Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. Circ J. 2005;69(1):83–88. doi: 10.1253/circj.69.83. PubMed DOI

Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014;18(1):R34. doi: 10.1186/cc13731. PubMed DOI PMC

Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem. 2001;276(15):12292–12300. doi: 10.1074/jbc.M007822200. PubMed DOI

Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44(3):571–577. PubMed

Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25(8):1369–1372. doi: 10.1016/j.peptides.2004.06.019. PubMed DOI

Di Somma S, Magrini L, Travaglino F, Lalle I, Fiotti N, Cervellin G, et al. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med. 2013;51(6):1167–1175. doi: 10.1515/cclm-2012-0795. PubMed DOI

Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.

Hartmann O, Schuetz P, Albrich WC, Anker SD, Mueller B, Schmidt T. Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection. Int J Cardiol. 2012;161(3):166–173. doi: 10.1016/j.ijcard.2012.09.014. PubMed DOI

Tzikas S, Keller T, Ojeda FM, Zeller T, Wild PS, Lubos E, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2013;99(6):388–395. doi: 10.1136/heartjnl-2012-302956. PubMed DOI

Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13(4):R122. doi: 10.1186/cc7975. PubMed DOI PMC

Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL., Jr Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33(17):2197–2205. doi: 10.1093/eurheartj/ehs136. PubMed DOI PMC

Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2011;58(10):1057–1067. doi: 10.1016/j.jacc.2011.06.006. PubMed DOI

Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186–2194. doi: 10.1016/j.ijcard.2013.01.228. PubMed DOI

Katayama T, Nakashima H, Honda Y, Suzuki S, Yano K. Relationship between adrenomedullin and left-ventricular systolic function and mortality in acute myocardial infarction. Angiology. 2005;56(1):35–42. doi: 10.1177/000331970505600105. PubMed DOI

Khan SQ, O’Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007;49(14):1525–1532. doi: 10.1016/j.jacc.2006.12.038. PubMed DOI

Luyt CE, Landivier A, Leprince P, Bernard M, Pavie A, Chastre J, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care. 2012;27(5):524e7-14. doi: 10.1016/j.jcrc.2011.12.009. PubMed DOI

Onitsuka H, Imamura T, Yamaga J, Kuwasako K, Kitamura K, Eto T. Angiotensin II stimulates cardiac adrenomedullin production and causes accumulation of mature adrenomedullin independently of hemodynamic stress in vivo. Horm Metab Res. 2005;37(5):281–285. doi: 10.1055/s-2005-861471. PubMed DOI

Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, et al. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun. 1995;207(1):25–32. doi: 10.1006/bbrc.1995.1148. PubMed DOI

Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 2005;25(12):2480–2487. doi: 10.1161/01.ATV.0000184759.91369.f8. PubMed DOI

von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12(5):484–491. doi: 10.1093/eurjhf/hfq031. PubMed DOI

Nishio K, Akai Y, Murao Y, Doi N, Ueda S, Tabuse H, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med. 1997;25(6):953–957. doi: 10.1097/00003246-199706000-00010. PubMed DOI

Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17(6):544–558. doi: 10.1002/ejhf.289. PubMed DOI

Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36(20):1223–1230. doi: 10.1093/eurheartj/ehv051. PubMed DOI

Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med. 2016;42(2):147–63. doi: 10.1007/s00134-015-4041-5. PubMed DOI

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;18(8):891–975. doi: 10.1002/ejhf.592. PubMed DOI

Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165(14):1643–1650. doi: 10.1001/archinte.165.14.1643. PubMed DOI

Task Force on the management of STseamiotESoC. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619. doi: 10.1093/eurheartj/ehs215. PubMed DOI

O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425. doi: 10.1161/CIR.0b013e3182742cf6. PubMed DOI

Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d’intervention. J Am Coll Cardiol. 2015;65(19):e7–e26. doi: 10.1016/j.jacc.2015.03.036. PubMed DOI

Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. Eur Heart J. 2014;35(3):156–167. doi: 10.1093/eurheartj/eht248. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01374867